Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;26(26):2100557.
doi: 10.2807/1560-7917.ES.2021.26.26.2100557.

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Yaniv Lustig  1   2 , Neta Zuckerman  1 , Ital Nemet  1 , Nofar Atari  1 , Limor Kliker  1 , Gili Regev-Yochay  2   3 , Einav Sapir  2   3 , Orna Mor  1   2 , Sharon Alroy-Preis  4 , Ella Mendelson  1   2 , Michal Mandelboim  1   2
Affiliations

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Yaniv Lustig et al. Euro Surveill. 2021 Jul.

Abstract

SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.

Keywords: B.1.617.2 (Delta); BNT162b2 vaccination; COVID-19; neutralizing; variants.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Phylogenetic tree of SARS-CoV-2 VOC Delta isolates originating in India
Figure 2
Figure 2
Neutralisation titres of individuals vaccinated with a second dose of Comirnatya against SARS-CoV-2 variants of concern
Figure 3
Figure 3
Fold change reduction compared to the original B.1 non-VOC SARS-CoV-2 in neutralising activity of VOCs
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 Clinical Trial Group . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29. 10.1016/S0140-6736(21)00947-8 - DOI - PMC - PubMed
    1. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-23. 10.1056/NEJMoa2101765 - DOI - PMC - PubMed
    1. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021;26(1). 10.2807/1560-7917.ES.2020.26.1.2002106 - DOI - PMC - PubMed
    1. Makoni M. South Africa responds to new SARS-CoV-2 variant. Lancet. 2021;397(10271):267. 10.1016/S0140-6736(21)00144-6 - DOI - PMC - PubMed